adherex technologies inc (AHX:Toronto)
adherex technologies inc (AHX) Snapshot
|
Open
C$0.98
|
Previous Close
C$1.00
|
|
|
Day High
C$1.02
|
Day Low
C$0.95
|
|
|
52 Week High
05/15/13 - C$1.02
|
52 Week Low
09/6/12 - C$0.10
|
|
|
Market Cap
25.2M
|
Average Volume 10 Days
37.0K
|
|
|
EPS TTM
C$-0.35
|
Shares Outstanding
25.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
adherex technologies inc (AHX) Related Businessweek News
No Related Businessweek News Foundadherex technologies inc (AHX) Details
Adherex Technologies Inc., together with its subsidiary, Adherex, Inc., operates as a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. It focuses on the development of Eniluracil, which is in phase II clinical trials to treat of cancer. Eniluracil is an irreversible inhibitor of dihydropyrimidine dehydrogenase, the enzyme primarily responsible for the rapid breakdown of 5-fluorouracil in the body. The company is also developing Sodium Thiosulfate, a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children, which is in phase III clinical trials. Adherex Technologies Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
adherex technologies inc (AHX) Top Compensated Officers
adherex technologies inc (AHX) Key Developments
Adherex Technologies Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations of $537,000 against $616,000 a year ago. Net loss and comprehensive loss was $4,108,000 against net profit and comprehensive profit of $2,715,000 a year ago. Basic net loss per common share was $0.16 against basic net income per share was $0.11 a year ago. The decrease in the net loss from operations excluding the non-cash impact of derivatives is primarily due to a reduction in research and development expenses.
Adherex Technologies Inc. announced audited consolidated earnings results for the year ended December 31, 2012. For the year, the company reported loss from operations of $3,620,000 against $3,438,000 a year ago. Net loss and comprehensive loss was $5,163,000 against $4,685,000 a year ago. Basic net loss per common share was $0.21 against $0.20 a year ago. The increase in the net loss from operations excluding the non-cash impact of derivative warrants is primarily due to an increase in research and development expenses of $0.6 million that was offset by decreased general and administrative expenses of $0.4 million in the comparable periods.
Adherex Technologies Inc. filed its 10-K on Apr 01, 2013 for the period ending Dec 31, 2012. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
| Recently Viewed | |||
| AHX:CN | C$1.00 CAD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for AHX. | |||
| View Industry Companies | |||
Industry Analysis
AHX
Industry Average
| Valuation | AHX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact ADHEREX TECHNOLOGIES INC, please visit www.adherex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








